Efficient Generation and Editing of Feeder-free IPSCs from Human Pancreatic Cells Using the CRISPR-Cas9 System
November 8th, 2017
9.8K views
This protocol describes in detail the generation of footprint-free induced pluripotent stem cells (iPSCs) from human pancreatic cells in feeder-free conditions, followed by editing using CRISPR/Cas9 ribonucleoproteins and characterization of the modified single-cell clones.
Overview
This protocol describes the generation of footprint-free induced pluripotent stem cells (iPSCs) from human pancreatic cells in feeder-free conditions, followed by editing using CRISPR/Cas9 ribonucleoproteins and characterization of the modified single-cell clones.
Key Study Components
Area of Science
- Stem Cell Biology
- Genetic Engineering
- Cell Culture Techniques
Background
- Induced pluripotent stem cells (iPSCs) are valuable for research and therapy.
- Footprint-free iPSCs avoid integration issues associated with traditional methods.
- CRISPR/Cas9 technology allows precise genome editing.
- Characterization of modified clones is essential for validating genetic changes.
Purpose of Study
- To generate footprint-free iPSCs from human pancreatic cells.
- To utilize CRISPR/Cas9 for editing these cells.
- To characterize the resulting modified single-cell clones.
Methods Used
- Coating six-well plates with cold collagen.
- Plating early passage human primary pancreatic cells in Prigrow III medium.
- Transduction with Sendai vector tubes for genome editing.
- Characterization of edited iPSC clones for reliability and mosaicism.
Main Results
- Successful generation of footprint-free iPSCs.
- High reliability in generating clonal lines of edited iPSCs.
- No evidence of mosaicism in the modified clones.
- Validated the effectiveness of CRISPR/Cas9 ribonucleoproteins.
Conclusions
- This method provides a reliable approach for generating and editing iPSCs.
- Footprint-free iPSCs can be used for various applications in research.
- CRISPR/Cas9 ribonucleoproteins are effective for precise genome editing.
Frequently Asked Questions
What are induced pluripotent stem cells (iPSCs)?
iPSCs are stem cells that can be generated directly from adult cells and have the ability to differentiate into any cell type.
Why is it important to generate footprint-free iPSCs?
Footprint-free iPSCs avoid the integration of foreign DNA, reducing potential risks in therapeutic applications.
What is the role of CRISPR/Cas9 in this protocol?
CRISPR/Cas9 is used for precise editing of the genome in the generated iPSCs.
How are the modified iPSC clones characterized?
The modified clones are characterized to ensure reliability and to check for mosaicism.
What are the advantages of using Sendai vectors?
Sendai vectors are non-integrating and allow for transient expression of the CRISPR components, minimizing genomic alterations.
Can this method be applied to other cell types?
Yes, this method can potentially be adapted for other types of human cells.
Executive Industry Relevance
This protocol enables reliable generation of footprint-free iPSCs from human pancreatic cells under feeder-free conditions, supporting disease modeling and therapeutic development in diabetes and regenerative medicine. By combining Sendai vector reprogramming with CRISPR-Cas9 RNP editing, it delivers clonal, mosaic-free lines with high efficiency, reducing attrition in target validation and lead identification workflows. The approach enhances predictive confidence in preclinical models by providing genetically defined, scalable human cell systems for mechanistic de-risking.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses in human pancreatic lineage through precise genome editing of iPSCs.
- Operational Value: Produces clonal, footprint-free iPSCs with no mosaicism, ensuring clean genetic backgrounds for target validation.
- Predictive Value: Supports predictive confidence by generating isogenic controls for pathway clarification and phenotypic screening.
Screening & Assay Development
- Scientific Value: Generates validated iPSC-derived pancreatic cells suitable for assay development in diabetes-related target screening.
- Operational Value: Enables scalable, reproducible production of edited iPSC clones for compound evaluation in 96-well formats.
- Assay Readiness: Delivers single-cell-sorted, genetically modified iPSCs with defined edits for consistent downstream screening.
Translational & Preclinical Research
- Translational Continuity: Provides disease-relevant human pancreatic iPSC models for preclinical validation of genetic targets.
- Mechanistic De-risking: Facilitates editing of disease-associated loci to assess target modulation and pathway biasing in human cells.
- Preclinical Model: Supports risk-adjusted advancement by generating clonal iPSC lines with validated on-target edits and no off-target integration.
Pipeline & Workflow Integration
The method integrates into the discovery continuum from early target hypothesis testing through lead identification to preclinical validation, enabling seamless transition from genetic editing to functional assessment in human cell models.
- Discovery Biology: Supports hypothesis testing via precise CRISPR-Cas9 editing of iPSCs derived from human pancreatic cells to clarify gene function in disease pathways.
- Screening: Enables assay-ready, clonal iPSC populations with defined genotypes for reproducible compound screening and target engagement studies.
- Analytics: Provides quantitative genotypic outputs via fragment analysis of PCR-amplified target regions, allowing comparison of edited versus wild-type clones.
- Translational Research: Connects discovery to preclinical work by delivering genetically modified human iPSCs with disease-relevant pancreatic phenotype for target validation.
- Enterprise Reuse: Establishes a reusable platform for generating and editing footprint-free iPSCs across multiple targets and projects, reducing redundant development.
Operational & Enterprise Impact
- Scientific Value: Delivers predictive confidence through mosaic-free, clonal iPSCs with precise biallelic edits for reliable target validation.
- Operational Value: Ensures standardization and scalability via feeder-free, single-cell-sorted workflows compatible with high-throughput editing.
- Strategic Value: Improves go/no-go decisions by reducing late-stage biological risk through early mechanistic de-risking in human cells.
- Portfolio Impact: Enables risk-adjusted prioritization by providing genetically validated iPSC clones for advancement decisions in regenerative medicine pipelines.
Implementation Considerations
- Requires expertise in stem cell culture, nucleofection, and single-cell sorting for successful iPSC generation and editing.
- Depends on Nucleofector equipment, CRISPR-Cas9 RNP complexes, and matrix membrane-coated plates for efficient delivery and clonal expansion.
- Necessitates cross-team standardization between cell culture, molecular biology, and analytics groups for consistent clone characterization.
- Involves adaptation considerations when extending to other cell types beyond human pancreatic cells, including optimization of reprogramming and editing efficiency.
- Includes practical limitations such as the need for aseptic technique during sorting and culture to maintain clone integrity and prevent contamination.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in iPSC editing?
Null hypothesis testing enables rigorous assessment of whether observed phenotypic changes in edited iPSCs are statistically significant and not due to random variation, supporting confident target validation decisions.
How does independent variable isolation fit the discovery pipeline in CRISPR-Cas9 iPSC editing?
Isolating the independent variable (e.g., specific gene edit) allows researchers to attribute phenotypic outcomes directly to the genetic modification, clarifying target mechanism in discovery workflows.
What quantitative dependent variable measurements enable target assessment in edited iPSCs?
Quantitative measurements such as allele-specific PCR amplification and fragment analysis enable precise quantification of editing efficiency and zygosity in single-cell clones, supporting objective target assessment.
Why do replication requirements matter for cross-functional collaboration in iPSC editing workflows?
Replication ensures that edited iPSC clones with desired genotypes can be consistently regenerated across experiments, enabling reliable data sharing between discovery, screening, and preclinical teams.
What statistical analysis capabilities are required before implementing CRISPR-Cas9 editing in iPSCs?
Statistical analysis capabilities are needed to evaluate editing efficiency, clonality, and phenotypic significance, ensuring that observed effects are robust and reproducible prior to implementation in target validation pipelines.
